Open Access

Overexpression of ZEB2‑AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia

  • Authors:
    • Xiaolan Shi
    • Jiao Li
    • Liang Ma
    • Lijun Wen
    • Qinrong Wang
    • Hong Yao
    • Changgeng Ruan
    • Depei Wu
    • Xinyou Zhang
    • Suning Chen
  • View Affiliations

  • Published online on: March 15, 2019     https://doi.org/10.3892/ol.2019.10149
  • Pages: 4935-4947
  • Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy with poor clinical outcomes. To determine whether the expression of the long non‑coding (lnc)RNA zinc finger E‑box binding homeobox 2 (ZEB2) antisense RNA 1 (ZEB2‑AS1) is associated with clinical outcomes, its expression was analyzed in a retrospective cohort of 62 AML and 10 non‑malignant cases. The results revealed that the expression of ZEB2‑AS1 lncRNA was notably high and closely associated with adverse clinical outcomes in AML cases compared with the non‑malignant cases, based on either modified Medical Research Council or European Leukemia Net risk stratification systems. Univariate analyses indicated that patients with a higher expression of ZEB2‑AS1 lncRNA had significantly shorter overall survival (OS) (P=0.036) and disease‑free survival (DFS) rates (P=0.039) compared with patients with a lower expression of ZEB2‑AS1 lncRNA. In addition, patients with a higher expression of ZEB2‑AS1 lncRNA had a significant lower complete remission rate in response to induction by chemotherapy compared with patients with a lower expression of ZEB2‑AS1 lncRNA (P=0.031). In cases with low levels of ZEB2‑AS1 lncRNA, patients treated with allogenic hematopoietic stem cell transplantation had significantly longer OS and DFS rates compared with that of chemotherapy‑treated patients (P=0.037 and P=0.049 respectively). Furthermore, the knockdown of ZEB2‑AS1 lncRNA effectively inhibited AML cell invasion and migration, which was closely associated with the downregulation of ZEB2 and upregulation of E‑cadherin expression. Collectively, although its independent prognostic value for survival was not rigorously determined, ZEB2‑AS1 lncRNA may function as a candidate marker to improve conventional risk stratification systems and the evaluation of therapeutic responses for AML.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Shi, X., Li, J., Ma, L., Wen, L., Wang, Q., Yao, H. ... Chen, S. (2019). Overexpression of ZEB2‑AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia. Oncology Letters, 17, 4935-4947. https://doi.org/10.3892/ol.2019.10149
MLA
Shi, X., Li, J., Ma, L., Wen, L., Wang, Q., Yao, H., Ruan, C., Wu, D., Zhang, X., Chen, S."Overexpression of ZEB2‑AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia". Oncology Letters 17.6 (2019): 4935-4947.
Chicago
Shi, X., Li, J., Ma, L., Wen, L., Wang, Q., Yao, H., Ruan, C., Wu, D., Zhang, X., Chen, S."Overexpression of ZEB2‑AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia". Oncology Letters 17, no. 6 (2019): 4935-4947. https://doi.org/10.3892/ol.2019.10149